Independently Carriage of *IL-1RN*2 Allele* Associated with Increased Risk of Gastric Cancer in The Sudanese Population.

Authors:

Abeer Babiker Idris,^{1#} Amany Eltayib Ataelmanan,^{2*} Sulafa Mohamed Eltaher,^{3*} Einas Babiker Idris,^{4#} Bashir M. Osman Arbab,⁵ Ahmed Ibn Idris,⁵ Mohamed Mansour,^{6,7} El-Amin Mohamed Ibrahim,¹ Mohamed A. Hassan.^{8,9}

*These authors contributed equally to this work

#Corresponding authors: abeer.babiker89@gmail.com; ens555@hotmail.com

¹Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum-Sudan

²Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, University of A-Jazirah, Al-Jazirah-Sudan

³The Academy of Health Sciences, The Republic of Sudan Federal Ministry of Health, Khartoum-Sudan

⁴Rashid Complex Medical Clinics, Riyadh-Saudi Arabia

⁵Modern Medical Centre, Khartoum-Sudan

⁶Ibin Sina specialized hospital, Khartoum-Sudan

⁷Soba University Hospital, Khartoum-Sudan

⁸Department of Bioinformatics, Africa city of technology, Khartoum-Sudan

⁹Department of Bioinformatics, DETAGEN Genetic Diagnostics Center, Kayseri-Turkey

Abstract

Background: *Helicobacter pylori* is responsible for gastric cancer in approximately tens of millions of patients. Gastric cancer in Sudan represents one of the top causing death among cancers with about 686 cases per year and a 2.7 % mortality rate. *IL-1RN* VNTR polymorphism has been reported to increase the risk of gastric cancer.

Objective: The purpose of this study was to assess the association of the 86 bp VNTR polymorphism of *IL-1RN* gene and the susceptibility to *H. pylori* infection and gastric cancer in the Sudanese population.

Materials and methods: Genomic DNA was extracted from 114 subjects. Of whom 60 had gastritis and duodenitis, 26 had a peptic ulcer, 16 had gastric cancer and 12 had normal gastroscopy findings. *H. pylori* infection was investigated by specific *16S rRNA*. And *IL-1RN* VNTR polymorphism at intron 2 was genotyped using the PCR method and direct sequencing for random samples.

Results: The positive *H. pylori* infection rate among participants was 47.37%. There is a lack of a significant difference in *IL-1RN* genotype with *H. pylori* infection (p-value=1.0000). The *IL-1RN* L/L genotype was significantly more frequent in a patient with benign disorders (gastritis or duodenitis or peptic ulcer), Odd=6.000 (95% CI =1.750-20.57, P=0.0056). While the heterozygote genotype 2/L was associated with an increased risk of gastric cancer with OR = 12.83 (95% CI = 1.261-130.6, P=0.0302).

Conclusion: Independently carriage of *IL-1RN* *2 allele was associated with increased risk of gastric cancer in the Sudanese population. Notwithstanding the relatively small sample size of the study population, our findings show that the host genetic can be a useful tool for identifying high-risk individuals among dyspeptic patients; and also underscore the role played by host genetics in gastric carcinogenesis. To the best of our knowledge, this is the first study in Sudan concerning this issue.

Keywords: *Helicobacter pylori*, gastric cancer, polymorphism, *IL-1RN*, VNTR, Sudan

1. Introduction

Helicobacter pylori infection is the most common human infection worldwide, approximately 50% of the world's populations are infected and this is made human the main reservoir for *H. pylori*.^(1, 2) Although the high infection rates among the world population, most of them develop no clinical symptoms and continue their life with chronic gastritis.⁽³⁻⁵⁾ Unfortunately, still high percentages of the infected populations might develop severe gastric pathology. Approximately 17% of them will develop peptic ulcers and one-quarter of such patients even experience ulcer complications,⁽⁶⁾ while (approximately 1%) will progress to gastric cancers.^(6, 7) In terms of numbers, it is expected that several hundreds of millions will suffer from peptic ulceration and tens of millions might progress to gastric cancer.⁽⁴⁾

The presence of a pro-inflammatory response and the level of gastric acid secretion contribute significantly to the development of either peptic ulcer disease or atrophic gastritis.^(8, 9) IL-1 family has a pivotal role in the innate immunity and regulatory functions in the adaptive immune system.⁽¹⁰⁾ IL-1 (IL-1 α and IL-1 β), is the most influencing pro-inflammatory cytokine while *IL-1RN* is a naturally occurring anti-inflammatory cytokine.⁽¹¹⁻¹³⁾ It is competitively bound to IL-1 receptors (IL-1R and IL-1RII), and thereby regulates the biological activity of IL-1 α and IL-1 β and modulates their potentially damaging effects.⁽¹⁴⁻¹⁸⁾ However, the therapeutic administration of IL-1ra, as a recombinant protein, has proven effective to prevent tissue damage⁽¹⁰⁾ and IL-1ra concentrations must be at least 100-fold higher than IL-1 β concentrations to functionally block the biologic effects of IL-1 β on target cells; hence, considerable production of IL-1ra is necessary for local tissues to stop the effects of IL-1 β .⁽¹⁹⁾

The *IL-1* genes cluster spanning approximately 430 kb, which is located on the long arm of human chromosome 2q13-21, comprising *IL-1A*, *IL-1B*, and *IL-1RN*. *IL-1RN* (Location: 2q14.1, MIM:147679) encodes IL-1ra, the endogenous receptor antagonist of IL-1 α and IL-1 β , using the functional part of IL-1 thereby modulates their potentially damaging effects on target cell.^(15, 20, 21) The *IL-1RN* gene has been linked with a broad range of chronic inflammatory diseases and enhanced IL-1 β secretion.^(11, 22-26) The imbalance between IL-1 and IL-1ra has a crucial impact in developing inflammatory

disorders in local tissues taking part in numerous illnesses, including infectious diseases, through overproduction of IL-1 α , β and/or underproduction of IL-1ra.⁽²⁷⁻²⁹⁾

Polymorphisms in *IL-1* and *IL-1RN* have been reported to be related to variations in the production levels of IL-1 (IL-1B and IL-1A) and IL-1ra.^(13, 30, 31) The most intensively studied IL-1RN polymorphism connected to susceptibility to *H. pylori* infection and gastric cancer outcome is a penta-allelic 86-bp VNTR (variable number of tandem repeats) polymorphism that is located in intron 2.^(12, 32-34) The most typical variants contains four repeats named allele *IL1RN*1* and variants with 2 repeats (allele *IL1RN*2*). While other alleles, 3 repeats (allele *IL1RN*4*), 5 repeats (allele *IL1RN*3*) and 6 repeats (allele *IL1RN*5*),⁽³⁵⁾ occur at a combined frequency of <5%.⁽¹⁴⁾ Vamvakopoulos *et. al.*, in 2000, revealed the sixth variant of this polymorphism containing only one repeat (allele *IL1RN*0*).⁽³⁶⁾ Studies from different ethnic groups have reported that in individuals infected with *H. pylori*, *IL-1RN*2* allele is associated with increased production of IL-1 β which leading to severe and sustained inflammation, gastric atrophy, hypochlorhydria, and ultimately to the development of gastric cancer.^(22, 31, 32, 37-39) Contrariwise, Asian studies have been less conclusive on the relation between *IL-1RN* polymorphism, *H. pylori* infection and gastric cancer.^(40, 41) It seems that there is an ethnic variability with regard to *IL-1RN* polymorphisms frequency and their association with *H. pylori* infection and gastric cancer. To the best of our knowledge, there have been no previous studies in Sudan have investigated the role of the *IL-1RN* polymorphisms in *H. pylori* infection and gastric cancer. Therefore, the purpose of this study was to assess the association of the 86 bp VNTR polymorphism of *IL-1RN* gene and the susceptibility to *H. pylori* infection and gastric cancer in the Sudanese population.

2. Materials and Methods

2.1 Ethical consideration

This study was approved by the Khartoum ministry of the health research department, University of Khartoum and Research Ethics Committees of hospitals.

2.2 Study design and Study sittings

The study was conducted in major public and private hospitals in mainly Khartoum state from June 2018 to January 2019. These hospitals include Ibin Sina specialized hospital which is a public hospital. And three private hospitals which include Modern Medical Centre, Al-Shorta hospital and Al Faisal Specialized Hospital. The distribution of participants' samples from hospitals in percentage is given in Figure1. All sample processes were carried out in the Molecular biological lab at the Faculty of Medical Laboratory Sciences at the University of Khartoum.

2.3 Study population

The study population composed of 114 subjects consisted of 54 *H. pylori* positive patients (33 male) of whom 29 had gastritis or/and duodenitis, 16 had a peptic ulcer, and 4 had gastric cancer, and 60 were *H. pylori* negative subjects (34 males) who regarded as controls, see Table 1. The subjects were recruited from the Endoscopy unit of public and private hospitals in Khartoum state. The diagnosis of gastroduodenal diseases was based on the assessment of an experienced gastroenterologist and the investigation of gastric cancer was confirmed by histopathology. The distribution of participants according to endoscopy series and clinical symptoms were presented in Tables 2 and 3, and Figure 2.

Each participant was interviewed using a structured questionnaire to seek information on residence, gastroenterological symptoms, and other variables. All interviews were conducted in the hospital before enrolling the participants. The selection criteria included the Sudanese population from both sexes, no antibiotic or NSAIDS uses. All the participants were informed with the objectives and purposes of the study and the written informed consents were taken.

Table1. Demographic characteristic of participants

Variables		Total n=114	<i>H. pylori</i> (+ve) n=54	<i>H. pylori</i> (-ve) n=60	P-value
Age years $\pm$ Std. Deviation (range)		44.91 $\pm$ 17.38 (15-89)	44.67 $\pm$ 16.79 (15-85)	45.13 $\pm$ 18.03 (17-89)	0.9864
Gender	Male	67 (58.77%)	33 (49.25%)	34 (50.75%)	0.7046
	Female	47 (41.23%)	21 (44.68%)	26 (55.32%)	
Residence	Urban	49 (42.98%)	19 (38.78%)	30 (61.22%)	0.132
	Rural	65 (57.02%)	35 (53.85%)	30 (46.15%)	
Hospital	Public	41 (35.96%)	13 (31.71%)	28 (68.29%)	0.019
	Private	73 (64.04%)	41 (56.16%)	32 (43.84%)	

Table 2. Distribution of participants according to endoscopy series and status of *H. pylori* infection

Endoscopy results	No.(%)	<i>H. pylori</i> (+ve)	<i>H. pylori</i> (-ve)	P-value
Normal gastric findings	12 (10.53%)	5 (41.67%)	7 (58.33%)	0.4319
Gastritis	55 (48.25)	27 (50%)	28 (46.67%)	
Duodenitis	5 (4.39%)	2 (3.70%)	3 (5%)	
Gastric ulcer	17 (14.91%)	11 (20.37%)	6 (10%)	
Duodenal ulcer	5 (4.39%)	3 (5.56%)	2 (3.33%)	
Gastroduodenal ulcers	4 (3.51%)	2 (3.70%)	2 (3.33%)	
Carcinoma	16 (14.03%)	4 (7.4%)	12 (20%)	
Total	114 (100%)	54 (100%)	60 (100%)	

Table 3. Distribution of participants according to clinical symptoms

Symptoms	No.	%
Gastrointestinal (GI) symptoms	102	89.47%
Liver cirrhosis	1	0.88%
Hepatosplenomegaly	2	1.75%
Iron deficiency anemia	1	0.88%
Others		
(10.53%)		
Membranous colitis	1	0.88%
Renal failure	1	0.88%
Pancreatic tumor	1	0.88%
Hernia	3	2.63%
Celiac disease	2	1.75%
Total	114	100%

2.4 Sample collection

A total of 114 gastric biopsies were collected in 1.5µl Eppendorf tubes with 400µl phosphate buffer saline (PBS). The biopsies were labeled and transported immediately to the molecular biological Lab then stored at -20°C until complete the collection of samples.

2.5 DNA extraction

The DNA extraction was done by using the innuPREP DNA Mini Kit (analytikjena AG, Germany) and performed according to the instructions of the manufacturing company. In a brief, the extraction procedure is based on a new kind of chemistry. First, lysis of biopsies which was done by adding 400µl of TLS and 25µl of proteinase K; and vortex for 5sec then incubation at 50°C until complete lysis occurred. Then, Centrifuging at 100rpm for 1min and transferring the supernatant to a new 1.5ml Eppendorf. Secondly, efficient binding of the DNA on a Spin Filter surface by adding 400µl of TBS and vortex for 15sec then adding the sample to the Spin Filter and centrifuge at 12000rpm for 2min.

thirdly, washing the bound DNA by adding 500µl HS and centrifuge at 12000rpm for 1min then adding 750µl MS and centrifuge at 12000rpm for 1min. Finally, eluting of the DNA by adding the Spin Filter to an Elution Tube then adding 200µl of the Elution Buffer and incubation for 1min at room temperature then centrifuged at 8000 for 1min. The extracted DNAs were stored at -20°C until further processing.

2.6 *H. pylori* 16S rRNA specific gene amplification

Extracted DNA was amplified for the specific 16S rRNA gene to investigate the infection of *H. pylori*. (primers: F:5'-GCGCAATCAGCGTCAGGTAATG-3') (R:5'-GCTAAGAGAGCAGCCTATGTCC-3').⁽⁴²⁾

PCR amplification was performed with Maxime PCR PreMix Kit (i-Taq) (iNtRON BIOTECHNOLOGY, Seongnam, Korea) and a PCR thermocycler (SensoQuest, Germany). The reaction mixtures used for PCR contained 2.5U of i-Taq TM DNA polymerase (5U/µl), 2.5mM of each deoxynucleoside tri- phosphates (dNTPs), 1X of PCR reaction buffer (10X), 1X of gel loading buffer and 1µl of DNA template. The temperature cycle for the PCR was an initial step of 3min at 94°C, followed by denaturation for 30sec at 94°C, annealing for 30sec at 53°C and primer extension for 45sec at 72°C. After the 40th cycle, the final extension step was prolonged for 5min to complete the synthesis of strands.

PCR products were detected by gel electrophoresis. 3µl of each PCR products was loaded onto 2% agarose gels stained with 3µl ethidium bromide (10mg/ml) and subjected to electrophoresis in 1x Tris EDTA Buffer (TEB buffer) (89mM of Tris base, 89mM Boric acid and 2mM EDTA dissolved in 1Litter H₂O) for 30 min at 120V and 50mA. The gel was visualized under UV light illumination. A 100MW DNA ladder (iNtRON BIOTECHNOLOGY, Seongnam, Korea) was included in each gel as a molecular size standard. The amplified products for the specific 16SrRNA gene is 522bp.

2.7 Detection of the IL-1RN 86bp VNTR at intron2 using conventional PCR

The IL-1RN 86bp VNTR was analyzes as previously described.⁽⁴³⁾ Briefly, oligonucleotides primers for PCR amplification were 5'-CTCAGCAACACTCCTAT-3'

and 5'-TCCTGGTCTGCAGGTAA-3'. The amplification conditions were 94°C for 1min, 35 cycles of 94°C for 1min, 60°C for 1min, 72°C for 1min, and a final extension at 72°C for 7 minutes. The PCR products were visualized by electrophoresis on a 2% agarose gel stained with ethidium bromide. A 1-kilobase DNA ladder was used to standardize alleles' sizes and code conventionally as follows: allele 1 (A1)=410bp (4 repeats), allele 2 (A2)=240bp (2 repeats), allele 3 (A3)=500bp (5 repeats), allele 4 (A4)=325bp (3 repeats), and allele 5 (A5)=595bp (6 repeats). For statistical analysis purposes and in accordance with a previous report conducted by Machado *et al.*, these alleles are classified into the short (allele *2=*2) and long alleles (alleles *1, *3, 4, and 5=L). The genotyping patterns will classify as L/L, L/*2, and *2/*2.^(38, 44)

3.8 Sequencing and sequence analysis

DNA purification and Sanger dideoxy sequencing were performed commercially by MacroGen Inc, Korea. For each sequence, two chromatograms (forward and reverse), were visualized and analyzed by using the Finch TV program version 1.4.0.⁽⁴⁵⁾ The Basic Local Alignment Search Tool (BLAST; <https://blast.ncbi.nlm.nih.gov/>) was used to look for and assess nucleotide sequence similarities; also to check the quality of our PCR procedure for detecting of VTRP *IL-1RN*.⁽⁴⁶⁾

2.9 Statistical analysis

Hardy-Weinberg equilibrium of genotype distributions was assessed by χ^2 test or Fisher's test. Descriptive statistical analysis was performed to calculate proportions, percentages, means, and standard deviations. According to the prevalence of *H. pylori* infection, differences in frequency distribution by age were assessed by the Mann-Whitney test. While differences in frequency distribution among the categorical demographic characteristics of the study population were examined with χ^2 test or Fisher's test. Associations of *IL-1RN* genotypes with *H. pylori* infection and endoscopic series were assessed by odd ratios (ORs) and 95% confidence intervals (CIs) using unconditional logistic regression analysis. Differences were considered to indicate statistical significance if $P < 0.05$. Data were analyzed using the Statistical Package for Social Sciences (SPSS version 19).

3. Result

The positive *H. pylori* infection rate among participants was 47.37%. No significant differences were noted for *H. pylori* infection rates by age, gender, and residence. A significant association was found with the type of hospitals ($p=0.019$) where participants from private hospitals involved a high percentage of infection.

Fifty-four patients and fifty-seven of sixty uninfected subjects were successfully typed for the *IL-1RN* polymorphism. In this study, six *IL-1RN* genotypes (1/1, 1/2, 2/2, 1/3, 2/3, and 1/4) were included while allele 5 (6 repeats) and allele 6 (0 repeats) of *IL-1ra* and homozygotes of the rare alleles (A3 and A4) were not detected in both groups of participants (infected and uninfected), see Figure 3. The frequency of *IL-1RN* alleles is presented in Table 4. *IL-1RN* allelic distributions did not deviate significantly from those expected in Hardy-Weinberg equilibrium for control subjects (for uninfected subjects $p=0.5923$; and for subjects with normal gastroscopy series $p=0.5983$).

The present study found a lack of a significant difference in *IL-1RN* genotype with *H. pylori* infection ($p\text{-value}=1.0000$), as shown in Table 5. The homozygote allele 2* (2/2 repeats) and the heterozygote allele 3* and allele 4* were found only in patients infected with *H. pylori*, one patient for each.

A profile of *IL-1RN* polymorphism in relation to gastric pathologies reveals that the *IL-1RN*L* allele was significantly associated with gastric pathologies risk if all patients were included ($P=0.0261$), see Table 6. The *IL-1RN L/L* genotype was significantly more frequent in a patient with benign disorders (gastritis or duodenitis or peptic ulcer), $\text{Odd}=6.000$ (95% CI = 1.750-20.57, $P=0.0056$), as shown in Table 7. Moreover, there is a significant association between gastric cancer and the carriage of *IL-1RN *2* allele ($P=0.0504$), see Table 6. The homozygous *ILRN 2/2* genotype was found in only one patient with antral gastritis while the heterozygote genotype 2/L was associated with an increased risk of gastric cancer with $\text{OR} = 12.83$ (95% CI = 1.261-130.6, $P=0.0302$). The risk for *IL-1RN*2* allele carriers increased by 15.75 (95% CI=1.448-171.3, $P = 0.0235$) as shown in Table 8. The gastric cancer risk was more evident for *IL-1RN 2/L* with $\text{OR}=18.00$ (95% CI = 1.631-198.6, $P = 0.0183$).(data not shown). However, the

calculation of the odds ratio of *ILRN* 2/L did not reach a statistical significance with gastritis/duodenitis or peptic ulcer, see Table 6 for more illustration.

Table 4. Four alleles of the *IL-IRN* 86bp VNTR at intron2 observed among participants

Allele	Frequency	Size (bp)	Number of repeats
A1	0.893	410	4 repeats
A2	0.094	240	2 repeats
A3	0.009	500	5 repeats
A4	0.004	325	3 repeats

Table 5. Allele and genotype frequencies of *IL-IRN* VNTR polymorphism among *H. pylori* infected and uninfected subjects, and their contributions to *H. pylori* infection

	<i>H. pylori</i> (+ve) n=54	<i>H. pylori</i> (-ve) n=57*	OR (95% CI)
Allele frequency			
<i>IL-1RN</i> *L	96 (88.89%)	103 (90.35%)	0.8544 (0.3600-2.028)
<i>IL-1RN</i> *2	12 (11.11%)	11 (9.65%)	
P-value	0.8267		
Genotype frequency			
L/L	43 (79.63%)	46 (80.70%)	1
2/L	10 (18.52%)	11 (19.30%)	1.028 (0.3968-2.665)
2/2	1 (1.85%)	0	0.3118 (0.01236-7.867)
2/L + 2/2	11 (20.37%)	11 (19.30%)	0.9348 (0.3675-2.378)
L/L * L/2+2/2	1.0000		
P-value			

*3 Samples are missing

Table 6. Allele and genotype frequencies of *IL-1RN* VNTR polymorphism in different gastric pathologies

Gastric pathologies							
	Normal finding n=12	Gastritis and / or Duodenitis n=60	OR (95% CI)	Peptic ulcer n=26	OR (95% CI)	Gastric cancer n=13	OR (95% CI)
Allele frequency							
<i>IL-1RN</i> *L	23 (95.8%)	109 (90.83%)	2.321 (0.2852-18.89)	48 (92.3%)	1.917 (0.2025-18.14)	19 (73.1%)	8.474 (0.9558-75.12)
<i>IL-1RN</i> *2	1 (4.16%)	11 (9.16%)		4 (7.69%)		7 (26.9%)	
P value	0.6908			1.0000		0.0504	
	0.0261						
Genotype frequency							
L/L	11 (91.67%)	50 (83.3%)	1	22 (84.6%)	1	6 (46.2%)	1
L/2	1 (8.3%)	9 (15%)	1.980 (0.2267-17.29)	4 (15.4%)	2.000 (0.1989-20.11)	7 (53.8%)	12.83 (1.261-130.6)
2/2	0	1 (1.67%)	0.6832 (0.0261-17.88)	0	-	0	-
L/2+2/2	1 (8.3%)	10 (16.67%)	2.200 (0.2544-19.03)	4 (15.4%)	2.000 (0.1989-20.11)	7 (53.8%)	12.83 (1.261-130.6)
L/L * L/2+2/2	0.6772			1.0000		0.0302	
P value	0.0109						

Table 7. *IL-1RN* VNTR polymorphism and gastric cancer association risk in gastric cancer patients and subjects with benign gastric disorders

Gastric pathologies			
	Benign disorders (gastritis or duodenitis or ulcer) n= 86	Cancer n=13	OR (95%CI)
Allele frequency			
IL-1RN*L	157	19	3.856 (1.396-10.65)
IL-1RN*2	15	7	
P-value	0.0131		
Genotype frequency			
L/L	72	6	6.000 (1.750-20.57)
2* Carrier	14	7	
P-value	0.0056		

Table 8. Gastric cancer risk association with *IL-1RN* polymorphism in 13 gastric cancer patients and 89 control subjects with normal findings or benign disorders according to *H. pylori* status

	<i>H. pylori</i> (+ve)		OR (95% CI)	<i>H. pylori</i> (-ve)		OR (95% CI)
	normal findings or Benign disorders*	Cancer		normal findings or Benign disorders*	Cancer	
Allele frequency						
IL-1RN*L	91 (91%)	5(62.5%)	6.067 (1.241-29.66)	89 (92.71%)	14(77.78%)	3.633
IL-1RN*2	9 (9%)	3(37.5%)		7 (7.29%)	4 (22.22%)	(0.940-14.04)
P-value	0.0432			0.0710		
Genotype frequency						
L/L	42 (84%)	1 (25%)	15.75 (1.448-171.3)	41 (85.42%)	5(55.56%)	4.686
2* Carrier	8 (16%)	3 (75%)		7 (14.85%)	4 (44.44%)	(1.004-21.86)
P-value	0.0235			0.0595		

*Benign disorders (gastritis or duodenitis or peptic ulcer)

4. Discussion

In this study, the analysis of *IL-1RN* 86bp VNTR polymorphism at intron 2 showed a significant association between gastric cancer and independently carriage of *IL-1RN* *2 allele (P=0.0504) in the Sudanese population. This finding is in agreement with other studies from Portugal, Italy, and the UK which also found that the presence of *IL-1RN* *2 increased the risk of gastric cancer.^(31, 38, 47, 48) Since 2000 when Omer *et al.*, reported the first significant association between gastric cancer risk and polymorphism in the genes *IL-1B* and *IL-1RN* among Scottish and Polish patients,⁽³¹⁾ a lot of studies from different ethnic groups and populations have pointed out this relation as well.^(32, 49, 50) Unfortunately, to the best of our knowledge, no data regarding these polymorphisms are available in Sudan where gastric cancer, according to GLOBOCAN 2018, represents one of the top causing death among cancers with about 686 cases per year and 2.7 % mortality rate.⁽⁵¹⁾ However, most of the studies have observed this association with an *IL-1RN* 2/2 homozygous genotype^(31, 38, 48) but we found this association with a heterozygous genotype (*IL-1RN* 2/L) with OR=12.83 (95% CI = 1.261-130.6, P = 0.0302) which is consistent with other studies conducted in Italy,^(47, 52) Brazil,⁽⁵³⁾ Taiwan,⁽⁵⁴⁾ China,⁽⁵⁵⁾ Turkey⁽³⁹⁾ and Arabic population (Omani and Algerian)^(56, 57) that found the same association of gastric cancer with a *IL-1RN* 2/L heterozygous genotype.

Moreover, the risk for *IL-1RN* *2 carriers increased by 15.75 (95% CI=1.448-171.3, P = 0.0235) in *H. pylori* infected patients. Similarly, a significantly increased risk of gastric cancer with *IL-1RN* *2 carriers who infected with *H. pylori* was noticed with a moderate increase among Hispanics, but not among the Asian population.^(23, 58-60) In 2005, Ruzzo *et al.* studied the potential etiologic role of *IL-1RN* VNTR polymorphism in *H. pylori*-negative, Italian gastric cancer patients. And he found that the *IL-1RN**2 allele may contribute to intestinal gastric cancer risk in the absence of concomitant *H. pylori* infection which suggests that the *IL-1RN**2 allele could contribute to disease risk independently.⁽⁴⁷⁾ However, other dietary environmental mutagens and carcinogens may interact with the pro-inflammatory cytokines on the gastric mucosa then induce gastric cancer even in the absence of *H. pylori* infection.^(61, 62) N-nitroso compounds and polycyclic aromatic hydrocarbons have been found to increase IL-1 β production levels.⁽⁶³⁻⁶⁵⁾ Moreover, *IL-1RN* and *IL-1B* have been reported to independently enhance cell proliferation and tumorigenesis.^(66, 67)

The variation in *IL-1RN* gastric cancer predisposition risk between studies could be due to the different genetic backgrounds in different ethnic groups or due in part to the variation in the frequency of the *IL-1RN* 2/2 homozygous genotype in the study populations. In our study, only one patient had *IL-1RN* 2/2 homozygous genotype and actually, a potential limitation of our investigation is the relatively small sample size. A low prevalence of *IL-1RN* allele 2 has observed previously in African-American⁽⁶⁸⁾ and black African populations.^(69, 70) The frequency of the *IL-1RN* *2 allele in the Sudanese study population was 9.4% which is low compared with 26% and 15% in Caucasian and Omani populations, respectively but high in comparison with the Asian population for whom frequencies of around 6% are reported.^(31, 41, 52, 56)

In the African population, data are scarce regarding the effects of *IL-1RN* VNTR polymorphism on gastric pathology. In this study, we found a significantly prevalent of *IL-1RN* L/L genotype in patients with benign disorders (gastritis or duodenitis or peptic ulcer), Odd=6.000 (95% CI =1.750-20.57, P=0.0056). This finding is in concordance partially with the result reported by Kimang' *et al.* in an African population in 2012 that

the *IL-1RN* L/L were significantly more frequent in *H. pylori* associated gastric pathologies (gastritis, peptic ulcer disease, and gastrointestinal reflux disease).⁽⁷⁰⁾

With regard to the susceptibility to *H. pylori* infection, we found a lack of association between *IL-1RN* 86bp VNTR polymorphism and susceptibility to *H. pylori* infection. This negative finding is similar to those reported in Japanese and UK populations.^(44, 71)

The true nature of the relationship between the polymorphisms of pro-inflammatory cytokines, susceptibility to *H. pylori* infection and development of gastric cancer is likely to be extremely complex and still unclear. Although the high prevalence of *H. pylori* infection (about 50% of the world's population), only 15% of these individuals go on to develop clinically significant diseases.⁽⁷²⁾ The accepted model for the variation in *H. pylori*-associated diseases relates to the amount of stomach acid secretion, the site of *H. pylori* colonization and the distribution of the infection; i.e., antral gastritis favors duodenal ulcer formation whereas corpus-predominant gastritis favors the development of a gastric ulcer and sometimes progressing to metaplasia and adenocarcinoma. The severe impaired acid secretion that typically results from diffuse gastritis allows *H. pylori* to colonize the corpus.^(73, 74) However, *IL-1B* and *IL-1RN* polymorphisms increase IL-1 β production which suppresses gastric acid secretion and therefore potentially influences *H. pylori* distribution within the stomach and predisposes individuals to gastric cancer.^(31, 37) These facts together lead us to suggest that the genetic association of *IL-1RN* polymorphisms with gastric cancer is a result of the complex interaction between the host inflammatory response and *H. pylori* but not primarily related to increased susceptibility to *H. pylori* infection. Moreover, a number of studies conducted in different ethnic groups showed an association between *IL-1RN* polymorphisms and *H. pylori*-mediated diseases (gastritis, duodenitis, ulcer, and cancer), see Table 9 for more illustration.

Table 9. Summary of published studies on the association between the susceptibility to *H. pylori* infection, gastroduodenal diseases and *IL-1RN* 86bp VNTR polymorphism in different ethnic groups

Author	Year	Country	Ethnicity	Screening method	Inference	Reference
Abeer	2019	Sudan	Sudanese	PCR and direct sequencing	<i>IL1-RN</i> 2/L increases risk of gastric cancer	This study
Lu W	2005	China	Chinese	PCR-based denaturing high-performance liquid chromatography analysis and direct DNA sequencing	No association between the susceptibility to <i>H. pylori</i> infection, gastric cancer and <i>IL-1RN</i> polymorphism	(40)
Kulmambetova	2014	Kazakhstan	Kazakh	PCR and direct sequencing	<i>IL1-RN</i> 2/2 with concomitant <i>H. pylori</i> infection increases risk of gastritis	(75)
Kumar	2009	Indian	India	PCR	<i>IL-1RN</i> 2/L increases the risk of gastric cancer in <i>H. pylori</i> infected patients. <i>IL-1RN</i> 2/2 increases the risk of gastric cancer in <i>H. pylori</i> uninfected patients.	(76)
Amine	2016	Algeria	Algerian	PCR	<i>IL1-RN</i> 2/L with concomitant <i>H. pylori</i> infection increases the risk of chronic atrophy gastritis.	(57)
Leea	2003	Korea	Korean	PCR	No association between <i>IL-1RN</i> polymorphism and gastric cancer or duodenal ulcer.	(41)
Santos	2012	Brazil	Brazilian	PCR	No association between gastric cancer and <i>IL-1RN</i> polymorphism	(77)
Neda	2017	Iran	Iranian	PCR	<i>IL1-RN</i> 2/L increases the risk of peptic ulcer	(30)
Rejane	2013	Brazil	Brazilian	PCR	<i>IL1-RN</i> 2/2 increases risk of gastric cancer while <i>IL1-RN</i> 2/L decreases the risk of gastric cancer <i>IL-1RN</i> 2/2 protects against <i>H. pylori</i> and peptic ulcer	(34)
Andrew	2012	Kenya	African	PCR-RFLP	<i>IL1-RN</i> 2/2 and <i>IL1-RN</i>	(70)

					L/L increase risk of <i>H. pylori</i> infection <i>IL-IRN</i> L/L are more frequent in <i>H. pylori</i> associated gastric pathologies	
Bang-Shun	2011	China	Chinese	PCR	<i>IL1-RN</i> 2/L with concomitant <i>H. pylori</i> infection increases the risk of gastric cancer	(55)
Mansour	2006	Oman	Omani Arab	PCR	<i>IL1-RN</i> 2/L with concomitant <i>H. pylori</i> infection increases the risk of gastric cancer	(56)
El-Omar	2000	Scotland and Poland	Scottish Polish Caucasian	PCR	<i>IL1-RN</i> 2/2 with concomitant <i>H. pylori</i> infection increases the risk of gastric cancer	(31)

H. pylori is an extremely common and highly genetically diverse bacteria that are able to alter the host physiology and immune response allowing it to persist for the life of the host. Eradication of *H. pylori* could be a double-edged sword, reducing the incidence of gastric pathologies and gastric cancer while increasing the risk of esophageal diseases and allergies. Many bacterial and Host genotypes act in concert to determine which individuals are at the highest risk of disease. The findings of our study indicate that the *IL-IRN* L/2 genotype is significantly associated with the risk of gastric cancer thus intervention (i.e., eradication treatment) aimed at patients with this genotype has the potential to reduce the risk of gastric cancer substantially.

Notwithstanding the limitations of the present study which include the relatively small number of participants, cross-sectional design, depending on *16S rRNA* for *H. pylori* investigation which did not exclude the previous infection of individual and the investigation has been done in only one gene (*IL-IRN*) without invoking other carcinogenic factors, our findings show that the host genetic can be a useful tool for identifying high-risk individuals among dyspeptic patients; and also underscore the role played by host genetics in gastric carcinogenesis. Further national studies with a large sample size are needed to determine the effect of host- and *H. pylori*- related genotypes on the development of gastric cancer.

In conclusion:

Independently carriage of *IL-1RN* *2 allele contributes significantly to the risk of gastric cancer in the Sudanese population. And this risk is further increased with concomitant *H. pylori* infection. Notwithstanding the relatively small sample size of the study population, our findings show that the host genetic can be a useful tool for identifying high-risk individuals among dyspeptic patients; and also underscore the role played by host genetics in gastric carcinogenesis.

Acknowledgment

We are very thankful to patients who participated in this study and to the staff of the gastroscopic unit in Ibin Sina specialized hospital, Modern Medical Centre, Al-Shorta hospital and Al Faisal Specialized Hospital.

Conflict of interest:

The authors declare that there are no conflicts of interest.

Supplementary material

The data regarding *IL-1RN* genotypes and alleles distributions among participants that used to support the findings of this study are included within the supplementary information file.

Funding Statement

The authors received no specific funding for this work.

References

1. Go M. Review article: Natural history and epidemiology of *Helicobacter pylori* infection. *Alimentary pharmacology & therapeutics*. 2002;16 Suppl 1:3-15.
2. Brown L. *Helicobacter Pylori: Epidemiology and Routes of Transmission*. *Epidemiologic reviews*. 2000;22:283-97.
3. Hunt RH. The role of *Helicobacter pylori* in pathogenesis: the spectrum of clinical outcomes. *Scand J Gastroenterol Suppl*. 1996;220:3-9.
4. Salih B. *Helicobacter pylori* infection in developing countries: The burden for how long? *Saudi Journal of Gastroenterology*. 2009;15(3):201-7.
5. Rothenbacher D, Brenner H. Burden of *Helicobacter pylori* and *H. pylori*-related diseases in developed countries: Recent developments and future implications. *Microbes and infection / Institut Pasteur*. 2003;5:693-703.
6. Sjomina O, Pavlova J, Niv Y, Leja M. Epidemiology of *Helicobacter pylori* infection. *Helicobacter*. 2018;23(S1):e12514.
7. Goh K-L, Chan W-K, Shiota S, Yamaoka Y. Epidemiology of *Helicobacter pylori* infection and public health implications. *Helicobacter*. 2011;16 Suppl 1(0 1):1-9.
8. Walduck AK, Raghavan S. Immunity and Vaccine Development Against *Helicobacter pylori*. *Advances in experimental medicine and biology*. 2019.
9. Sato M, Miura K, Kageyama C, Sakae H, Obayashi Y, Kawahara Y, et al. Association of host immunity with *Helicobacter pylori* infection in recurrent gastric cancer. *Infectious agents and cancer*. 2019;14:4.
10. Arend W. The balance between IL-1 and IL-1Ra in disease. *Cytokine & growth factor reviews*. 2002;13:323-40.
11. Mesa F, Lanza E, Garcia L, Marfil-Alvarez R, Magan-Fernandez A. Polymorphism IL-1RN rs419598 reduces the susceptibility to generalized periodontitis in a population of European descent. *PloS one*. 2017;12(10):e0186366.
12. Chmiela M, Karwowska Z, Gonciarz W, Allushi B, Staczek P. Host pathogen interactions in *Helicobacter pylori* related gastric cancer. *World journal of gastroenterology*. 2017;23(9):1521-40.

13. Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in *Helicobacter pylori* infection. *Gastroenterology*. 2002;123(6):1793-803.
14. Singh H, Samani D, Nema V, Ghate MV, Gangakhedkar RR. IL-1RN and IL-1beta Polymorphism and ARV-Associated Hepatotoxicity. *Mediators of inflammation*. 2018;2018:4398150.
15. Dinarello C. Biologic basis for interleukin-1 in disease. *Blood*. 1996;87(6):2095-147.
16. Eisenberg SP, Brewer MT, Verderber E, Heimdal P, Brandhuber BJ, Thompson RC. Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism. *Proc Natl Acad Sci U S A*. 1991;88(12):5232-6.
17. Iizuka N, Hazama S, Hirose K, Abe T, Tokuda N, Fukumoto T, et al. Interleukin-1 receptor antagonist mRNA expression and the progression of gastric carcinoma. *Cancer letters*. 1999;142(2):179-84.
18. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. *Annual review of immunology*. 1998;16:27-55.
19. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. *J Clin Invest*. 1990;85(5):1694-7.
20. Fields JK, Günther S, Sundberg EJ. Structural Basis of IL-1 Family Cytokine Signaling. *Front Immunol*. 2019;10:1412-.
21. Nicklin MJH, Weith A, Duff GW. A Physical Map of the Region Encompassing the Human Interleukin-1 α , Interleukin-1 β , and Interleukin-1 Receptor Antagonist Genes. *Genomics*. 1994;19(2):382-4.
22. Akcil G, Dogan I, Cengiz M, Engin ED, Dogan M, Unal S, et al. The role of interleukin-1 gene polymorphisms and *Helicobacter pylori* in gastroesophageal reflux disease. *The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology*. 2014;25 Suppl 1:81-5.
23. Camargo MC, Mera R, Correa P, Peek RM, Jr., Fontham ET, Goodman KJ, et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric

cancer: a meta-analysis. *Cancer epidemiology, biomarkers & prevention* : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006;15(9):1674-87.

24. Arman A, Yilmaz B, Coker A, Inanc N, Direskeneli H. Interleukin-1 receptor antagonist (IL-1RN) and interleukin-1B gene polymorphisms in Turkish patients with rheumatoid arthritis. *Clinical and experimental rheumatology*. 2006;24(6):643-8.

25. Tolusso B, Pietrapertosa D, Morelli A, De Santis M, Gremese E, Farina G, et al. IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. *Pharmacogenomics*. 2006;7(5):683-95.

26. Lee KM, Park SK, Hamajima N, Tajima K, Choi JY, Noh DY, et al. Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women. *Breast cancer research and treatment*. 2006;96(2):197-202.

27. Rad R, Prinz C, Neu B, Neuhofer M, Zeitner M, Voland P, et al. Synergistic effect of *Helicobacter pylori* virulence factors and interleukin-1 polymorphisms for the development of severe histological changes in the gastric mucosa. *The Journal of infectious diseases*. 2003;188(2):272-81.

28. Figueiredo CA, Marques CR, Costa Rdos S, da Silva HB, Alcantara-Neves NM. Cytokines, cytokine gene polymorphisms and *Helicobacter pylori* infection: friend or foe? *World journal of gastroenterology*. 2014;20(18):5235-43.

29. Barlik M, Mrozikiewicz AE, Drews-Piasecka E, Kurzawinska G, Malewski Z, Drews K. The relevance of IL-1beta and IL-1RN gene polymorphisms in the etiology of preterm delivery in the population of Polish women. *Ginekologia polska*. 2019;90(4):212-6.

30. Motamedi Rad N, Rezaeishahmirzadi M, Shakeri S, Abbaszadegan MR, Shekari M. Association of IL-1B+3954 and IL-1RN Polymorphisms in Chronic Gastritis and Peptic Ulcer. *Iranian journal of public health*. 2018;47(9):1364-70.

31. El-Omar EM, Carrington M, Chow W-H, McColl KEL, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature*. 2000;404(6776):398-402.

32. Zhang J, Sun X, Wang J, Zhang F, Li X, Han J. Association of the IL-1RN variable number of tandem repeat polymorphism and Helicobacter pylori infection: A meta-analysis. *PloS one*. 2017;12(4):e0175052.
33. Figueiredo CA, Marques CR, Costa RdS, da Silva HBF, Alcantara-Neves NM. Cytokines, cytokine gene polymorphisms and Helicobacter pylori infection: friend or foe? *World journal of gastroenterology*. 2014;20(18):5235-43.
34. Mattar R, Marques SB, Dos Santos AF, do Socorro Monteiro M, Iriya K, Carrilho FJ. A possible role of IL-1RN gene polymorphism in the outcome of gastrointestinal diseases associated with H. pylori infection. *Clinical and experimental gastroenterology*. 2013;6:35-41.
35. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. *Human genetics*. 1993;91(4):403-4.
36. Vamvakopoulos J. Interleukin 1 gene polymorphisms. *Ann Rheum Dis*. 2001;60(7):718-9.
37. El-Omar EM. The importance of interleukin 1beta in Helicobacter pylori associated disease. *Gut*. 2001;48(6):743-7.
38. Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C, et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. *Gastroenterology*. 2001;121(4):823-9.
39. Erzin Y, Koksall V, Altun S, Dobrucali A, Aslan M, Erdamar S, et al. Role of host interleukin 1beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in clinical outcomes in Helicobacter pylori-positive Turkish patients with dyspepsia. *Journal of gastroenterology*. 2008;43(9):705-10.
40. Lu W, Pan K, Zhang L, Lin D, Miao X, You W. Genetic polymorphisms of interleukin (IL)-1B, IL-1RN, IL-8, IL-10 and tumor necrosis factor {alpha} and risk of gastric cancer in a Chinese population. *Carcinogenesis*. 2005;26(3):631-6.
41. Lee SG, Kim B, Choi W, Lee I, Choi J, Song K. Lack of association between pro-inflammatory genotypes of the interleukin-1 (IL-1B -31 C/+ and IL-1RN *2/*2) and gastric cancer/duodenal ulcer in Korean population. *Cytokine*. 2003;21(4):167-71.

42. Carbone M, Maugeri TL, Gugliandolo C, La Camera E, Biondo C, Fera MT. Occurrence of *Helicobacter pylori* DNA in the coastal environment of southern Italy (Straits of Messina). *J Appl Microbiol.* 2005;98(3):768-74.
43. JK T, AI B, A L, R S, HN H, A S, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. *Hum Genet.* 1993;91(4):403-4.
44. Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. *Gastroenterology.* 2002;123(1):92-105.
45. FinchTV. 1.4.0 ed. USA: Geospiza, Inc.; Seattle, WA,; 2012.
46. Altschul SF, Madden TL, Schäffer AA, J Zhang ZZ, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST. A new generation of protein database search programmes. *Nucleic Acids Res.* 1997;25(17):3389–402.
47. Ruzzo A, Graziano F, Pizzagalli F, Santini D, Battistelli V, Panunzi S, et al. Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in *Helicobacter pylori*-negative gastric cancer of intestinal and diffuse histotype. *Annals of oncology : official journal of the European Society for Medical Oncology.* 2005;16(6):887-92.
48. Zambon CF, Basso D, Navaglia F, Germano G, Gallo N, Milazzo M, et al. *Helicobacter pylori* virulence genes and host IL-1RN and IL-1beta genes interplay in favouring the development of peptic ulcer and intestinal metaplasia. *Cytokine.* 2002;18(5):242-51.
49. Kamangar F, Cheng C, Abnet CC, Rabkin CS. Interleukin-1B polymorphisms and gastric cancer risk--a meta-analysis. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.* 2006;15(10):1920-8.
50. Zhang Y, Liu C, Peng H, Zhang J, Feng Q. IL1 receptor antagonist gene IL1-RN variable number of tandem repeats polymorphism and cancer risk: a literature review and meta-analysis. *PloS one.* 2012;7(9):e46017-e.

51. Parkin DM FJ, Jemal A, Borok M, Manraj SS, N'da GG, Ogunbiyi FJ, Liu B, Bray F. Cancer in Sub-Saharan Africa. Lyon: International Agency for Research on Cancer.: IARC Scientific Publication

2018. Available from: <http://publications.iarc.fr/>.

52. Palli D, Saieva C, Luzzi I, Masala G, Topa S, Sera F, et al. Interleukin-1 gene polymorphisms and gastric cancer risk in a high-risk Italian population. The American journal of gastroenterology. 2005;100(9):1941-8.

53. Rocha GA, Guerra JB, Rocha AMC, Saraiva IEB, da Silva DA, de Oliveira CA, et al. IL1RN polymorphic gene and cagA-positive status independently increase the risk of noncardia gastric carcinoma. International journal of cancer. 2005;115(5):678-83.

54. Chen A, Li CN, Hsu PI, Lai KH, Tseng HH, Hsu PN, et al. Risks of interleukin-1 genetic polymorphisms and Helicobacter pylori infection in the development of gastric cancer. Alimentary pharmacology & therapeutics. 2004;20(2):203-11.

55. He BS, Pan YQ, Xu YF, Zhu C, Qu LL, Wang SK. Polymorphisms in interleukin-1B (IL-1B) and interleukin 1 receptor antagonist (IL-1RN) genes associate with gastric cancer risk in the Chinese population. Digestive diseases and sciences. 2011;56(7):2017-23.

56. Al-Moundhri MS, Al-Nabhani M, Al-Bahrani B, Burney IA, Al-Madhani A, Ganguly SS, et al. Interleukin-1beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms and gastric cancer risk in an Omani Arab population. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2006;9(4):284-90.

57. Drici Ael M, Moulessehou S, Tifrit A, Diaf M, Turki DK, Bachir M, et al. Effect of IL-1beta and IL-1RN polymorphisms in carcinogenesis of the gastric mucosa in patients infected with Helicobacter pylori in Algeria. The Libyan journal of medicine. 2016;11:31576.

58. Xue H, Lin B, Ni P, Xu H, Huang G. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. Journal of gastroenterology and hepatology. 2010;25(10):1604-17.

59. Persson C, Canedo P, Machado JC, El-Omar EM, Forman D. Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE

systematic review and meta-analyses. American journal of epidemiology. 2011;173(3):259-70.

60. Bonequi P, Meneses-Gonzalez F, Correa P, Rabkin CS, Camargo MC. Risk factors for gastric cancer in Latin America: a meta-analysis. Cancer causes & control : CCC. 2013;24(2):217-31.

61. Palli D, Saieva C, Coppi C, Del Giudice G, Magagnotti C, Nesi G, et al. O6-alkylguanines, dietary N-nitroso compounds, and their precursors in gastric cancer. Nutrition and cancer. 2001;39(1):42-9.

62. Bertuccio P, Rosato V, Andreano A, Ferraroni M, Decarli A, Edefonti V, et al. Dietary patterns and gastric cancer risk: a systematic review and meta-analysis. Annals of Oncology. 2013;24(6):1450-8.

63. Schook LB, Lockwood JF, Yang SD, Myers MJ. Dimethylnitrosamine (DMN)-induced IL-1 beta, TNF-alpha, and IL-6 inflammatory cytokine expression. Toxicology and applied pharmacology. 1992;116(1):110-6.

64. Uedo N, Tatsuta M, Iishi H, Baba M, Yano H, Ishihara R, et al. Enhancement by interleukin-1 beta of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats: a possible mechanism for Helicobacter pylori-associated gastric carcinogenesis. Cancer letters. 2003;198(2):161-8.

65. Tamaki A, Hayashi H, Nakajima H, Takii T, Katagiri D, Miyazawa K, et al. Polycyclic aromatic hydrocarbon increases mRNA level for interleukin 1 beta in human fibroblast-like synoviocyte line via aryl hydrocarbon receptor. Biological & pharmaceutical bulletin. 2004;27(3):407-10.

66. Beales IL. Effect of interleukin-1beta on proliferation of gastric epithelial cells in culture. BMC gastroenterology. 2002;2:7.

67. Song X, Voronov E, Dvorkin T, Fima E, Cagnano E, Benharroch D, et al. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. Journal of immunology (Baltimore, Md : 1950). 2003;171(12):6448-56.

68. Rider LG, Artlett CM, Foster CB, Ahmed A, Neeman T, Chanock SJ, et al. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clinical and experimental immunology. 2000;121(1):47-52.

69. Bellamy R, Kwiatkowski D, Hill AVS. Absence of an association between intercellular adhesion molecule 1, complement receptor 1 and interleukin 1 receptor antagonist gene polymorphisms and severe malaria in a West African population. *Transactions of The Royal Society of Tropical Medicine and Hygiene*. 1998;92(3):312-6.
70. Kimang'a AN. IL-1B-511 Allele T and IL-1RN-L/L Play a Pathological Role in Helicobacter Pylori (H. Pylori) Disease Outcome in the African Population. *Ethiopian journal of health sciences*. 2012;22(3):163-9.
71. Hartland S, Newton JL, Griffin SM, Donaldson PT. A functional polymorphism in the interleukin-1 receptor-1 gene is associated with increased risk of Helicobacter pylori infection but not with gastric cancer. *Digestive diseases and sciences*. 2004;49(9):1545-50.
72. Chang W-L, Yeh Y-C, Sheu B-S. The impacts of H. pylori virulence factors on the development of gastroduodenal diseases. *J Biomed Sci*. 2018;25(1):68-.
73. Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. *Clin Microbiol Rev*. 2006;19(3):449-90.
74. Testerman TL, Morris J. Beyond the stomach: An updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. *World journal of gastroenterology*. 2014;20(36):12781-808.
75. Kulmambetova GN, Imanbekova MK, Logvinenko AA, Sukashev AT, Filipenko ML, Ramanculov EM. Association of cytokine gene polymorphisms with gastritis in a Kazakh population. *Asian Pacific journal of cancer prevention : APJCP*. 2014;15(18):7763-8.
76. Kumar S, Kumar A, Dixit VK. Evidences showing association of interleukin-1B polymorphisms with increased risk of gastric cancer in an Indian population. *Biochemical and biophysical research communications*. 2009;387(3):456-60.
77. Santos JC, Ladeira MSP, Pedrazzoli Jr J, Ribeiro ML. Relationship of IL-1 and TNF- $\pm$ polymorphisms with Helicobacter pylori in gastric diseases in a Brazilian population. *Brazilian Journal of Medical and Biological Research*. 2012;45:811-7.

Figure 1. Distribution of participants among hospitals

Figure 2. Shows clinical symptoms of participants

Figure3. 3a) and 3b) Illustrate PCR products analyzed on a 2% agarose gel stained with ethidium bromide. Four different alleles can be seen at 240bp, 325bp, 410bp and 500bp representing 2, 3, 4 and 5 copies of the 86-bp sequence, respectively. 3c) shows the sequencing result of the chromatogram using Finch TV software. The 4 nucleotide sequences of the *IL-IRN* containing 86bp VNTR polymorphism were deposited in the GenBank database under the following accession numbers: from MN641824 to MN641829